Navigation Links
Sangamo BioSciences and Collaborators Present Data Showcasing Broad Applications of ZFP Therapeutics®
Date:5/23/2011

RICHMOND, Calif., May 23, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that data from clinical, preclinical and research-stage programs focused on the development of zinc finger DNA-binding protein (ZFP) Therapeutics® were described in twenty presentations given by Sangamo scientists and collaborators at the 14th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT).  The meeting was held in Seattle from May 18-21, 2011.

"Sangamo's ZFP technology is revolutionizing cell and gene therapies," stated Barrie Carter, Ph.D., a member of Sangamo's scientific advisory board and President of ASGCT for 2010-2011. "ZFP Nuclease (ZFN) technology provides an efficient and precise process for editing any DNA sequence in a cell, making development of therapeutic gene-editing applications a reality.  Sangamo has ongoing human clinical trials to evaluate ZFN-based therapeutics in HIV/AIDS and ZFP transcription factors (ZFP TFs) in neuroregeneration. As this technology functions at the DNA level, it can be applied to numerous diseases and any disease-related gene."

ASGCT meeting presentations included previously described preliminary clinical data from Sangamo's ongoing Phase 1 clinical trial in HIV/AIDS (SB-728-902) as well as data from preclinical and research-stage human therapeutic programs.  Therapeutic areas included ZFN-based approaches to infectious diseases such as HIV/AIDS and monogenic diseases such as hemophilia, ADA-SCID, retinal neurodegeneration and epidermolysis bullosa.  Positive preclinical data were also presented from studies of Sangamo's ZFP TF activator of the vascular endothelial growth factor-A (VEGF-A) gene in an animal model of stroke.

"These data presentations illustrate the broad range of potential applications for ZFP Therapeutics including monogenic diseases,
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sangamo BioSciences Announces Presentation at the Cowen and Company 31st Annual Health Care Conference
2. Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections
3. Sangamo BioSciences Announces Presentation at the 13th Annual BIO CEO & Investor Conference
4. Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
5. Sangamo BioSciences Announces Presentation at Lazard Capital Markets Healthcare Conference
6. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
7. Sangamo BioSciences Receives Michael J. Fox Foundation Funding to Develop Novel Drug for the Treatment of Parkinsons Disease
8. Sangamo BioSciences Announces First Quarter 2010 Conference Call and Webcast
9. Sangamo BioSciences Announces Fourth Quarter and Full Year 2009 Conference Call and Webcast
10. Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
11. Sangamo Announces Closing of Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... , March 31, 2015  CVS Health (NYSE: ... into new clinical affiliations with Rush University Medical ... and Tucson Medical Center in Tucson, ... Arizona Connected Care. These affiliations will help enhance ... patients. Through these clinical affiliations, CVS Health will ...
(Date:3/31/2015)... , March 31, 2015  Oxis International, Inc. (OXIS) ... development and commercialization, announced today Oxis CEO Tony ... of Oxis common shares on the Euronext exchange. Oxis ... the symbol OXIS.   Oxis Chairman and ... to move forward with its strategies launched in 2014 ...
(Date:3/31/2015)... MIAMI , March 31, 2015 ... TALOS™, today announced a strategic partnership with ... solutions for clinical research in life sciences. Offering ... global CRO has deployed Medidata,s electronic data capture ... support Biorasi,s Phase I through IV global clinical ...
Breaking Medicine Technology:CVS Health Announces New Clinical Affiliations with Leading Medical Centers in Arizona and Illinois 2CVS Health Announces New Clinical Affiliations with Leading Medical Centers in Arizona and Illinois 3Oxis International Inc. Announces Request for Euronext Trading Suspension 2Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 2Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 3Biorasi Selects Medidata's Cloud-Based Platform for Optimal Trial Operations 4
... 15, 2012 ViroPharma Incorporated,s (Nasdaq: VPHM ) ... expected to be released on Tuesday, February 28, 2012 before ... company will host a conference call and live audio webcast ... the conference call, ViroPharma management will discuss the 2011 fourth ...
... is a compelling example of the life-changing importance of organ ... decision to donate his wife,s organs in hopes of helping ... when he received a donor heart transplant after 120 days ... . (Photo: http://photos.prnewswire.com/prnh/20120215/LA53807 ) ...
Cached Medicine Technology:ViroPharma to Release 2011 Fourth Quarter and Full Year Financial Results on February 28, 2012 2Total Artificial Heart Patient Receives Donor Heart 15 Years After Decision to Donate Wife's Organs 2Total Artificial Heart Patient Receives Donor Heart 15 Years After Decision to Donate Wife's Organs 3Total Artificial Heart Patient Receives Donor Heart 15 Years After Decision to Donate Wife's Organs 4
(Date:3/31/2015)... (PRWEB) March 31, 2015 Karen A. ... 2015 at Rivier University’s Commencement ceremony on ... of humane letters in recognition of her eminent career ... Serving as a front-line caregiver and senior staff nurse ... years and advancing to leadership roles, including President of ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 Indosoft, developer of ... Asterisk 1.4 support in development of their 5.x line. The ... Asterisk has been deployed around the world for more than ... 1.4 as a telephony platform, Q-Suite can fully embrace newer ... quality call center software on Asterisk for more than a ...
(Date:3/31/2015)... CA (PRWEB) March 31, 2015 ... joins BayBio’s Membership Program , the premiere ... the region’s 1300+ life science companies. , ... of the world’s most innovative and productive life ... to solve some of humanity’s most pressing challenges. ...
(Date:3/31/2015)... March 31, 2015 Healthpointe’s team of ... at all of their clinics. Specialties include hip dislocations, ... , For athletes with hip injuries, Healthpointe has a ... and treat the symptoms and underlying causes of the ... care and prevent future damage, while taking into consideration ...
(Date:3/31/2015)... OR (PRWEB) March 31, 2015 Former 49ers ... announcement than during his first year of a promising NFL ... Sports on Earth Senior Writer Will Leitch explores ... the league. Leitch talks about the decision making process that ... the preservation of health over a large paycheck, and what ...
Breaking Medicine News(10 mins):Health News:Rivier University to recognize nurse leader, educator and safety advocate at 80th Commencement on May 9th 2Health News:Rivier University to recognize nurse leader, educator and safety advocate at 80th Commencement on May 9th 3Health News:Indosoft Announces End of Life for Asterisk 1.4 Support in Q-Suite 5 Call Center Software 2Health News:Clinovo Joins BayBio Membership Program, The Leading Life Science Association in Northern California 2Health News:Healthpointe Now Treating Hip Dislocations, Hip Fractures, Hip Bursitis, and Hip Strains at Locations in Southern California 2Health News:Will Leitch and the Curious Case of Chris Borland on SCI TV 2Health News:Will Leitch and the Curious Case of Chris Borland on SCI TV 3
... THURSDAY, Dec. 23 (HealthDay News) -- Eating a vegetarian diet ... the blood and urine, says a small new study. ... -- which is found in dietary proteins and is a ... themselves of the mineral. In these patients, high levels of ...
... pathway known as Wnt, commonly activated in cancers, causes ... enzyme that is vital in degrading proteins, preventing the ... of many proteins within the cell, researchers at UCLA,s ... is important because sequestering the enzyme, Glycogen Synthase Kinase ...
... , WEDNESDAY, Dec. 22 (HealthDay News) -- Confronting the ... are unaware they are taking dummy pills, researchers found ... fake still reported significant symptom relief. In a ... a control group received no treatment while the other ...
... HealthDay Reporter , THURSDAY, Dec. 23 (HealthDay News) -- Liz Smith ... The first signs of arthritis in Emily, now 18, appeared when ... Burke, Va. "She slipped in a swimming pool and had a ... the beginning of all of it." For several months, the ...
... of vascular diseases may also contribute to the failure ... dialysis patients, according to a study appearing in an ... Society of Nephrology (JASN). "Our findings raise ... to the relatively poor outcomes regarding the function and ...
... Dec. 22 (HealthDay News) -- A gene mutation that ... glioblastoma brain cancer has been identified by researchers. ... -- contributes to tumor development, promotes resistance to treatment ... with glioblastoma, the most common and deadly type of ...
Cached Medicine News:Health News:Vegetarian Diet Cuts Kidney Patients' Levels of Toxic Phosphorus 2Health News:UCLA researchers uncover new cell biological mechanism that regulates protein stability in cells 2Health News:Placebos Work -- Even if Patients Are in on the Secret 2Health News:Placebos Work -- Even if Patients Are in on the Secret 3Health News:Lifetime of Arthritis Has Not Held Back Teen 2Health News:Lifetime of Arthritis Has Not Held Back Teen 3Health News:Why does dialysis fail? 2Health News:Gene Mutation Found in One of Four Cases of Deadly Brain Cancers 2
... vascular closure device quickly seals ... procedures, allowing for early ambulation ... creates a mechanical seal by ... bio-absorbable anchor and collagen sponge, ...
Terumo's Optitorque offers superior torque and precision control. It's patient-friendly, high torque design makes it the catheter of choice for demanding angiography....
Jography angiographic catheter has a new material combination, a patented angled weld, a flat wire braid design with a XXL lumen. It also has an atraumatic soft tip....
Femoral selective catheter. Catheter material used is polyurethane (TRICOR). Guidewire campatibility is 0.038". Packaging 5/Box....
Medicine Products: